Clinical pharmacology and therapy
February 3, 2025
Andriy A Gorbenko, Jules A A C Heuberger, Maria J Juachon et al.
Emergency department visits due to cannabinoid‐induced toxicity, including acute cannabinoid intoxication (ACI) have increased worldwide as more states have liberalized cannabis policy. ACI symptoms include anxiety, panic attacks, tachycardia, and psychosis, primarily mediated through cannabinoid type 1 receptor (CB1) agonism by Δ9‐tetrahydrocannabinol (THC). This phase II randomized,...
Clinical Pharmacology & Therapeutics
November 1, 2024
Andriy A Gorbenko, Jules A A C Heuberger, Linda E. Klumpers et al.
17 citations
Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the tolerability of cannabis as an analgesic. A...
Journal of Psychopharmacology
August 12, 2023
Michael Tagen, Daniel Mantuani, Alex Holstein et al.
39 citations
Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...
British Journal of Pharmacology
August 1, 2022
Michael Tagen, Linda E. Klumpers
The use of the intoxicating cannabinoid delta‐8‐tetrahydrocannabinol (Δ8‐THC) has grown rapidly over the last several years. There have been dozens of Δ8‐THC studies dating back over many decades, yet no review articles have comprehensively covered these findings. In this review, we summarize the pharmacological studies of Δ8‐THC, including receptor binding, cell signalling, in vivo...
Brain Connectivity
December 2015
Daniel Kleinloog, Serge A.r.b. Rombouts, Remco Zoethout et al.
This analysis examines the neuronal foundation of drug-induced psychomimetic symptoms by relating the severity of these symptoms to changes in functional connectivity for a range of different psychoactive compounds with varying degrees of psychomimetic effects. The repeated measures design included 323 resting-state functional magnetic resonance imaging time series and measures of subjective...
British Journal of Clinical Pharmacology
July 2013
Linda E. Klumpers, Christine Roy, Geraldine Ferron et al.
Cannabinoid receptor type 1 (CB1 ) antagonists have been developed for the treatment of obesity and associated risk factors. Surinabant is a high affinity CB1 antagonist in vitro. The aim of this study was to assess the magnitude of inhibition by surinabant of CNS effects and heart rate induced by Δ(9) -tetrahydrocannabinol (THC) in humans. This was a double-blind, placebo-controlled,...
Neuroimage
November 15, 2012
Linda E. Klumpers, David M. Cole, Najmeh Khalili-Mahani et al.
Resting state-functional magnetic resonance imaging (RS-FMRI) is a neuroimaging technique that allows repeated assessments of functional connectivity in resting state. While task-related FMRI is limited to indirectly measured drug effects in areas affected by the task, resting state can show direct CNS effects across all brain networks. Hence, RS-FMRI could be an objective measure for compounds...
British Journal of Clinical Pharmacology
July 2012
Linda E. Klumpers, Tim L Beumer, Johan G C Van Hasselt et al.
• Cannabis based medicines are registered as a treatment for various indications, such as pain and spasms in multiple sclerosis (MS) patients, and anorexia and nausea in patients with HIV or receiving cancer treatment. • the pharmacokinetics of the various administration routes of cannabis and cannabis based medicines are variable and dosing is hard to regulate. • Namisol is a new tablet...